Xian Tang - Jafron Biomedical Deputy Director

300529 Stock   29.96  0.10  0.33%   

Director

Xian Tang is Deputy Director of Jafron Biomedical Co
Age 54
Address No. 98 Technology Six Road, Zhuhai, China, 519085
Phone86 75 6368 9708
Webhttps://www.jafroninternational.com

Jafron Biomedical Management Efficiency

The company has return on total asset (ROA) of 0.1052 % which means that it generated a profit of $0.1052 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2476 %, meaning that it generated $0.2476 on every $100 dollars invested by stockholders. Jafron Biomedical's management efficiency ratios could be used to measure how well Jafron Biomedical manages its routine affairs as well as how well it operates its assets and liabilities. At present, Jafron Biomedical's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 272.2 M, whereas Intangible Assets are forecasted to decline to about 53.5 M.

Similar Executives

Showing other executives

DIRECTOR Age

Xuewen ZhangPostal Savings Bank
62
Fanggen LiuChina Construction Bank
N/A
Hong YaoPostal Savings Bank
58
Wei WangBank of China
61
Zhang ShouchuanBank of China
N/A
Jingzhen LinBank of China
59
Lixin RenPetroChina Co Ltd
56
Guoyu ZhengIndustrial and Commercial
57
Pizheng LiChina Mobile Limited
58
Jiuyong YinBank of Communications
56
Xuguang ZhangAgricultural Bank of
60
Wanfu ZhouBank of Communications
59
Fuxiao ShenPetroChina Co Ltd
54
Zhihong JiChina Construction Bank
55
Cunxing DuBank of China
N/A
Ronghua LiChina Mobile Limited
58
Fangzheng JiaoPetroChina Co Ltd
61
Li LinAgricultural Bank of
56
Jafron Biomedical Co (300529) is traded on Shenzhen Stock Exchange in China and employs 2,408 people. Jafron Biomedical is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Jafron Biomedical Leadership Team

Elected by the shareholders, the Jafron Biomedical's board of directors comprises two types of representatives: Jafron Biomedical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jafron. The board's role is to monitor Jafron Biomedical's management team and ensure that shareholders' interests are well served. Jafron Biomedical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jafron Biomedical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Xiaolian He, Chief Officer
De Li, Deputy Manager
Xueyun Liao, Financial Controller
Cong Huang, Board Secretary
Xian Tang, Deputy Director
Fan Dong, GM Directors
Guang Zhang, Deputy Director
Aijun Wu, Deputy Manager
Kui Jin, Deputy Mang
Kai Zeng, Deputy Director
Rui Wang, General Manager

Jafron Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jafron Biomedical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Jafron Stock

Jafron Biomedical financial ratios help investors to determine whether Jafron Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Jafron with respect to the benefits of owning Jafron Biomedical security.